JP2023530231A5 - - Google Patents
Info
- Publication number
- JP2023530231A5 JP2023530231A5 JP2022574770A JP2022574770A JP2023530231A5 JP 2023530231 A5 JP2023530231 A5 JP 2023530231A5 JP 2022574770 A JP2022574770 A JP 2022574770A JP 2022574770 A JP2022574770 A JP 2022574770A JP 2023530231 A5 JP2023530231 A5 JP 2023530231A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- hydrogen
- heteroaryl
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034248P | 2020-06-03 | 2020-06-03 | |
| US63/034,248 | 2020-06-03 | ||
| US202163183094P | 2021-05-03 | 2021-05-03 | |
| US63/183,094 | 2021-05-03 | ||
| PCT/US2021/035343 WO2021247634A1 (en) | 2020-06-03 | 2021-06-02 | Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530231A JP2023530231A (ja) | 2023-07-14 |
| JP2023530231A5 true JP2023530231A5 (enExample) | 2024-06-12 |
Family
ID=76641834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574770A Withdrawn JP2023530231A (ja) | 2020-06-03 | 2021-06-02 | 転写増強アソシエートドメイン（ｔｅａｄ）阻害剤及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240124406A1 (enExample) |
| EP (1) | EP4164752A1 (enExample) |
| JP (1) | JP2023530231A (enExample) |
| AU (1) | AU2021283892A1 (enExample) |
| CA (1) | CA3180846A1 (enExample) |
| WO (1) | WO2021247634A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| BR112023014751A2 (pt) * | 2021-01-25 | 2023-10-03 | Ikena Oncology Inc | Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão |
| AR125350A1 (es) * | 2021-04-16 | 2023-07-12 | Orion Corp | Inhibidores tead |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| IL310924A (en) | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
| EP4464693A4 (en) * | 2022-01-14 | 2025-10-29 | Daewoong Pharmaceutical Co Ltd | NEW AMINOBENZENE DERIVATIVE WITH A CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING IT AS THE ACTIVE INGREDIENT |
| WO2023146511A1 (en) * | 2022-01-25 | 2023-08-03 | Vivace Therapeutics, Inc. | Compounds and methods of use thereof |
| TWI878871B (zh) * | 2022-05-09 | 2025-04-01 | 大陸商浙江同源康醫藥股份有限公司 | 多環類化合物及其用途 |
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
| WO2024088399A1 (zh) * | 2022-10-27 | 2024-05-02 | 勤浩医药（苏州）有限公司 | 含磷化合物、药物组合物及其应用 |
| WO2024099435A1 (zh) * | 2022-11-10 | 2024-05-16 | 武汉人福创新药物研发中心有限公司 | Tead抑制剂 |
| CN121443583A (zh) * | 2023-06-14 | 2026-01-30 | 赛诺哈勃药业（成都）有限公司 | 一种调控tead活性的化合物、其制备方法及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003257666A1 (en) * | 2002-08-23 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| CA2747419C (en) * | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| US11186554B2 (en) * | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| WO2019040380A1 (en) * | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | BENZOSULFONYL COMPOUNDS |
| WO2019113236A1 (en) * | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
| GB201810668D0 (en) * | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| EP3873474A4 (en) * | 2018-10-30 | 2022-07-13 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS |
| US11458149B1 (en) * | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
-
2021
- 2021-06-02 US US18/000,049 patent/US20240124406A1/en not_active Abandoned
- 2021-06-02 AU AU2021283892A patent/AU2021283892A1/en not_active Abandoned
- 2021-06-02 CA CA3180846A patent/CA3180846A1/en active Pending
- 2021-06-02 JP JP2022574770A patent/JP2023530231A/ja not_active Withdrawn
- 2021-06-02 WO PCT/US2021/035343 patent/WO2021247634A1/en not_active Ceased
- 2021-06-02 EP EP21735521.3A patent/EP4164752A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210126036A (ko) | 화합물, 조성물 및 방법 | |
| KR102354411B1 (ko) | 항바이러스제로서 유용한 아미노티아졸 유도체 | |
| CN108699059B (zh) | 可用于治疗正粘病毒感染的三环化合物 | |
| CN107108492B (zh) | 细胞坏死抑制剂 | |
| KR102708082B1 (ko) | 항바이러스 화합물로서 치환된 티아졸의 거울상 이성질체 | |
| JP2019527682A5 (enExample) | ||
| CN110167939B (zh) | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 | |
| CN114539246A (zh) | 一种哌啶并嘧啶类化合物及其用途 | |
| JP2019514883A5 (enExample) | ||
| JP2023508982A5 (enExample) | ||
| KR102678977B1 (ko) | Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법 | |
| TW201920115A (zh) | 化合物、組合物及方法 | |
| KR102212981B1 (ko) | 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약 | |
| AU2007225678A1 (en) | Quinolone derivative or pharmaceutically acceptable salt thereof | |
| JP2022513846A5 (enExample) | ||
| CN103002742A (zh) | 核转运调节剂及其应用 | |
| JP2013506715A5 (enExample) | ||
| CN107207486A (zh) | 用于抑制布罗莫结构域和末端外蛋白质的方法和组合 | |
| KR20230035049A (ko) | 화합물, 조성물 및 방법 | |
| JP2017517555A (ja) | 阻害剤ｐ５３−Ｍｄｍ２タンパク質−タンパク質相互作用としての、１，１’，２，５’−テトラヒドロスピロ［インドール−３，２’−ピロール］−２，５’−ジオン系を含む化合物 | |
| TW201900613A (zh) | Ep 拮抗劑 | |
| WO2018117196A1 (ja) | がん幹細胞を標的とする医薬 | |
| JP2024517183A5 (enExample) | ||
| JP2021534084A5 (enExample) | ||
| CN111630043B (zh) | 含环化合物、其制备方法及其在医药上的应用 |